Core Insights - Silo Pharma, Inc. announced the issuance of a patent for pharmacological prophylactics against stress-induced affective disorders in females, with the patent number projected to be 12,239,614, effective March 4, 2025 [1][2][3] Patent and Product Development - The new patent reinforces protection for Silo's lead asset, SPC-15, which is an intranasal treatment targeting post-traumatic stress disorder (PTSD) and includes newly added claims to an existing patent [2][3] - SPC-15 is a serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders, with potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway, which could accelerate the approval process [4] Strategic Collaborations - Silo Pharma is collaborating with Columbia University to conduct preclinical studies for SPC-15, and the company holds exclusive global rights for its development and commercialization [4][5] - The CEO emphasized that strategic IP and patent expansion is crucial for advancing SPC-15 to clinical trials and enhancing the overall value of the company's pipeline [3]
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment